Pomerantz LLP has filed a class action lawsuit against ADMA Biologics, Inc. over potential securities fraud or unlawful business practices. Investors who purchased or acquired ADMA securities during the Class Period have until August 10, 2026 to seek appointment as Lead Plaintiff. The lawsuit follows a March 24, 2026 short report from Culper Research alleging that ADMA's reported growth was driven by channel stuffing and an undisclosed related party distributor, causing the stock to fall $2.26 per share, or 16.63%, to close at $11.33. Two days later, Cantor Fitzgerald downgraded ADMA, citing an inadequate response to the Culper report, and the stock fell an additional $1.34 per share, or 13.91%, to close at $8.29.
ADMA Biologics IncClass action lawsuit and short report alleging channel stuffing and undisclosed related party distributor, causing stock drop and downgrade.
